The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $55.16, representing a -2.56% change from its previous close.

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Scientists at Georgia State University have used CRISPR gene editing to restore an ancient enzyme humans lost millions of years ago potentially reversing the buildup of uric acid that causes gout.

Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Scientists are beginning to comprehend how a paradigm shift will alter what is known about the cell. However, IDPs already ...

His decoding of the blueprint for life with Francis H.C. Crick made him one of the most important scientists of the 20th ...

The report identifies seven deep-tech domains with the potential to drive agricultural transformation: generative artificial ...

Discover how a novel acceleration technique allows for the creation of transgenic and gene-edited crops without tissue ...

Rising rural-to-urban migration, intensifying climate extremes, and accelerating degradation of natural resources, ...

The Hippo signaling pathway that helps control tissue size in animals and malfunctions in cancers already existed before ...